Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,035 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sugar Pill Placebo Clear all
Terminated Phase 2 Interventional Results available

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

NCT02137252
View directory record Official record
Conditions
Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma, Fatigue Related to Cancer Treatment
Interventions
Naltrexone, Sugar Pill
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Phase 2Phase 3 Interventional

Acamprosate in the Treatment of Binge-Eating Disorder

NCT00511940
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
acamprosate, placebo
Drug · Other
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Sep 16, 2026, 5:45 PM EDT
Withdrawn Phase 2 Interventional

4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy

NCT03658408
View directory record Official record
Conditions
Prostate Disease
Interventions
4-aminopyridine, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
45 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 16, 2026, 5:45 PM EDT
Terminated Phase 3 Interventional

Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance

NCT00585208
View directory record Official record
Conditions
Insomnia, Bipolar Disorder
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Sep 16, 2026, 5:45 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Anti-oxidant Therapy and Postoperative Cardiac Events (ACE) Trial, Preoperative Intervention in Vascular Surgery

NCT03956017
View directory record Official record
Conditions
Myocardial Injury
Interventions
Ubiquinone, Placebo
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
Not listed
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Sep 16, 2026, 5:45 PM EDT
Not listed Phase 2 Interventional

A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD

NCT03339258
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Doxazosin Mesylate, Extended Release, Placebo
Drug
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Escitalopram Effects on CSF Amyloid Beta

NCT02161458
View directory record Official record
Conditions
Amyloid Beta Protein
Interventions
Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years to 85 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 16, 2026, 5:45 PM EDT
Terminated Phase 4 Interventional Results available

Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder

NCT01337609
View directory record Official record
Conditions
Major Depressive Disorder, Irritable Bowel Syndrome
Interventions
Ganeden BC30, Placebo (sugar pill), Ganeden BC30, Placebo (sugar pill)
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Burlington, Massachusetts • Westborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Sep 16, 2026, 5:45 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Androxal in Male Infertility

NCT02160704
View directory record Official record
Conditions
Infertility
Interventions
Enclomiphene citrate, Placebo
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 35 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 16, 2026, 5:45 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study to Determine Effectiveness of Activation Mist on Facial Skin Wrinkles

NCT01939964
View directory record Official record
Conditions
Skin Wrinkles on Face and Neck Areas
Interventions
Activation Mist
Other
Lead sponsor
California Allergy and Asthma Medical Group, Inc.
Other
Eligibility
30 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Sep 16, 2026, 5:45 PM EDT
Terminated Phase 2 Interventional Results available

Interventional Bioremediation of Microbiota in Metabolic Syndrome

NCT02730962
View directory record Official record
Conditions
Pre-Diabetes
Interventions
Vancomycin, Placebo, Neomycin, Clindamycin, Fecal Microbiota Transplantation
Drug · Other · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Atomoxetine Treatment for ADHD and Marijuana Dependence

NCT00360269
View directory record Official record
Conditions
Marijuana Abuse, Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Motivational enhancement therapy, Placebo
Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 16, 2026, 5:45 PM EDT
Terminated Phase 4 Interventional Results available

Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients

NCT02946580
View directory record Official record
Conditions
Constipation
Interventions
MOVANTIK™ (naloxegol), Sugar Pill
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
View directory record Official record
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Results available

A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents

NCT02714062
View directory record Official record
Conditions
Pediatric Obesity, Childhood Obesity
Interventions
Placebo, VI-0521 Mid Dose, VI-0521 Top Dose
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Marrero, Louisiana • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder

NCT02511886
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Arbaclofen Placarbil, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Oakland Park, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

Pharmacological Treatment for Alcoholism

NCT00382642
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Ondansetron + Cognitive Behavioral Therapy, Placebo + Cognitive Behavioral Therapy
Drug
Lead sponsor
Bankole Johnson
Other
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Selinexor in Advanced Liposarcoma

NCT02606461
View directory record Official record
Conditions
Dedifferentiated Liposarcoma
Interventions
Selinexor, Placebo
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
12 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

Effects of Low-Dose Doxycycline on Oral Bone Loss

NCT00066027
View directory record Official record
Conditions
Periodontitis
Interventions
20 mg doxycycline hyclate, Placebo
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Lincoln, Nebraska • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Not applicable Interventional

Optimizing Overactive Bladder Treatment

NCT03904407
View directory record Official record
Conditions
Overactive Bladder
Interventions
Lactobacillus Probiotic Capsule, Matching Lactobacillus Probiotic Placebo Capsule
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Hillsborough, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Results available

Modafinil for Treatment of Fatigue in ALS Patients

NCT00614926
View directory record Official record
Conditions
Fatigue
Interventions
Modafinil, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2012 · Synced Sep 16, 2026, 5:45 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)

NCT01272778
View directory record Official record
Conditions
Healthy Subjects
Interventions
Lorazepam, Placebo
Drug
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2011 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VA106483 Dose Response in Females

NCT01171391
View directory record Official record
Conditions
Nocturia
Interventions
VA106483, Placebo
Drug · Other
Lead sponsor
Vantia Ltd
Industry
Eligibility
40 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2010 · Synced Sep 16, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse

NCT01953432
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 16, 2026, 5:45 PM EDT